Pulmonary arterial hypertension trials in Latvia
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
- Where
- Riga
- Age
- 18 years and over
- People
- 85 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-513613-12-00 · EU 2024-513613-12-00 - Phase 2Taking peopleStudy of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
- Where
- Riga
- Age
- 18 years and over
- People
- 99 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07318597 · EU 2024-514754-79-00 - Phase 3Taking peopleA Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- Where
- Riga
- Age
- 18 years to 80 years
- People
- 344 worldwide
- Run by
- Liquidia Technologies, Inc.
See details and how to joinNCT07285655 - Phase 3Taking peopleOpen-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- Where
- Riga
- Age
- 18 years to 75 years
- People
- 330 worldwide
- Run by
- Gossamer Bio USA, Inc.
See details and how to joinNCT06274801 · EU 2023-506334-75-00 - Phase 2Taking peopleA Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- Where
- Riga
- Age
- 18 years to 80 years
- People
- 40 worldwide
- Run by
- AllRock Bio, Inc.
See details and how to joinNCT07175038 · EU 2025-522074-37-00 - Phase 3Taking peopleAn Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- Where
- Riga
- Age
- 18 years to 75 years
- People
- 486 worldwide
- Run by
- Inhibikase Therapeutics
See details and how to joinNCT07365332 · EU 2024-520218-23-00 - Phase 1/2Taking peopleA Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
- Where
- Riga
- Age
- 18 years to 100 years
- People
- 232 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06649110 - Phase 3Not yet taking people in LatviaA Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
- Where
- Riga
- Age
- 18 years to 75 years
- People
- 300 worldwide
- Run by
- VIVUS LLC
See details and how to joinNCT07612657 · EU 2025-524596-24-00